Consider Ingrezza When Treatment Is Needed for Tardive Dyskinesia

June 2017

The approval of Ingrezza (in-GREH-zah, valbenazine) will raise questions about how to treat tardive dyskinesia.

Up to 30% of patients on long-term antipsychotics develop tardive dyskinesia. It's usually associated with higher doses, longer duration, and higher-potency typical antipsychotics, such as haloperidol.

But it can also occur with atypical antipsychotics, such as risperidone...and other dopamine blockers, such as metoclopramide.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote